Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024

On Thursday, Emergent BioSolutions Inc. (NYSE:EBS) stock is trading higher on mixed third-quarter earnings and a new mpox trial in Africa.

The company reported third-quarter sales of $293.8 million, up 9% year over year, with the management guidance of $265 million–$315 million, and missing the consensus of $297.5 million.

The company reported an adjusted EPS of $1.37, a turnaround from a loss of $1.09 a year ago, beating the consensus of $0.14.

Revenues from Narcan (naloxone HCl) Nasal Spray decreased 33% to $95.3 million, primarily driven by the discontinuation of prescription Narcan due to the launch of over-the-counter Narcan in the third quarter of 2023 and lower Canadian retail sales, partially offset by higher sales of OTC Narcan.

Also ...